8-K: Teknova Reports Modest Revenue Growth for 2024, Projects Continued Improvement in 2025

Alpha Teknova reports a 3% increase in full-year 2024 revenue and provides 2025 revenue guidance of $39-42 million.

Summary

• Alpha Teknova, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2024.
• Full year 2024 total revenue reached $37.7 million, a 3% increase compared to $36.7 million in 2023, aligning with the company's guidance.
• Fourth quarter 2024 total revenue was $9.3 million, an 18% increase compared to $7.9 million in the same quarter of the previous year.
• The company achieved a 41% annual growth in the number of Clinical Solutions customers in 2024.
• At the end of 2024, total cash and short-term investments were $30.4 million, while gross debt was $12.1 million.
• Free Cash Flow for the full year 2024 was negative $13.5 million, a significant improvement from the negative $26.7 million in 2023 and better than the previously communicated target of negative $16 million.
• Teknova amended and extended its credit facility, setting a new maturity date in March 2030 with no scheduled principal repayments until April 2028.
• The company projects total revenue of $39 million to $42 million for the fiscal year ending December 31, 2025.
• Teknova anticipates full-year free cash outflow of less than $12 million for 2025.

Sentiment

Score: 7

Explanation: The sentiment is cautiously optimistic. While revenue growth is modest and gross profit declined, the company improved its free cash flow and extended its credit facility. The 2025 outlook is positive, but risks remain.

Positives

• The company achieved a 3% increase in full-year 2024 revenue, reaching $37.7 million.
• Fourth quarter 2024 revenue increased by 18% to $9.3 million.
• The number of Clinical Solutions customers grew by 41% in 2024.
• Free Cash Flow improved significantly, reaching negative $13.5 million for 2024, compared to negative $26.7 million in 2023.
• The credit facility was amended and extended to March 2030, with principal repayments starting in April 2028.
• The company projects total revenue of $39 million to $42 million for the fiscal year ending December 31, 2025.
• Teknova anticipates full-year free cash outflow of less than $12 million for 2025.

Negatives

• Gross profit for 2024 was $7.2 million, compared to $10.3 million in 2023.
• Gross margin for 2024 was 19.2%, compared to 28.1% in 2023.
• Net loss for 2024 was $26.7 million, or negative $0.57 per diluted share, compared to $36.8 million, or negative $1.16 per diluted share, for 2023.
• Adjusted EBITDA for 2024 was negative $14.5 million, compared to negative $19.8 million for 2023.

Risks

• The company's future performance is subject to risks and uncertainties, including demand for Teknova's products, supply chain issues, and global economic uncertainties.
• Reliance on a limited number of customers for a high percentage of Teknova's revenue poses a risk.
• Potential acquisitions and integration of other companies could present challenges.

Future Outlook

Teknova anticipates total revenue of $39 million to $42 million for the fiscal year ending December 31, 2025, and free cash outflow of less than $12 million for 2025.

Management Comments

• Stephen Gunstream, President and Chief Executive Officer at Teknova, stated that he is very proud of the company's execution in 2024.
• Stephen Gunstream believes the combination of the diversity of the company's catalog research reagents and custom researchand clinical-grade reagents positions Teknova for long-term sustainable growth.
• Matt Lowell, Teknova's Chief Financial Officer, noted the strong financial results in 2024 compared to 2023, including a return to top line growth and a significant improvement in adjusted EBITDA and free cash outflow.
• Matt Lowell attributed the outcomes to cost savings enacted throughout the year and good stewardship of capital.
• Matt Lowell explained that based on the 2025 revenue guidance of $39-42 million, the company anticipates full-year free cash outflow of less than $12 million.

Industry Context

The announcement reflects Teknova's efforts to navigate a dynamic market environment and position itself for long-term sustainable growth in the life sciences industry, particularly in the areas of novel therapies, vaccines, and molecular diagnostics.

Comparison to Industry Standards

• It is difficult to provide a direct comparison to industry standards without knowing Teknova's specific market segments and competitors.
• However, the reported revenue growth and improved free cash flow suggest positive momentum compared to the previous year.
• Companies like Thermo Fisher Scientific, Danaher Corporation, and Agilent Technologies are major players in the life sciences industry, but their diversified portfolios make direct comparisons challenging.
• Investors should consider Teknova's performance relative to smaller, more specialized reagent manufacturers and the overall growth rate of the specific market segments it serves.

Stakeholder Impact

• Shareholders: The results show modest growth and improved financial management, which could positively influence investor confidence.
• Employees: Cost-saving measures, including reduced headcount, may impact employee morale.
• Customers: The focus on high-quality reagents and customizable solutions aims to benefit customers in the life sciences industry.
• Creditors: The amended and extended credit facility provides financial stability and flexibility.

Next Steps

• Teknova will attend the TD Cowen 45th Annual Health Care Conference on March 5, 2025.
• Teknova will attend the KeyBanc Capital Markets Healthcare Forum on March 19, 2025.

Key Dates